$9B Bain Fund Has Life Sciences In Its Sights

Lab work
A New $3B Bain Fund Seeks To Invest In A Variety Of Assets, With A Focus On Life Sciences And Labs.

Bain Capital has closed a mammoth $3B fund to invest in U.S. property, including life sciences real estate, a sign of the incredible appetite for lab assets and other more specialized sectors including industrial and entertainment properties.

With leverage, the fund has the potential to invest nearly $9B, Bloomberg reports.

This is the second such fund created by the Boston-based private investment firm, double the size of the first fund. It has already has invested in life sciences real estate in San Francisco.

Funds in North America have roughly $225B to spend on property right now, per Preqin, a private markets data firm.

It’s not a great leap to expect a significant portion of both Bain’s funds and property funds in general will chase life sciences and lab assets. A new CBRE report released earlier this month underscored the unmet demand for such real estate despite increased development across major markets. The amount of lab space under speculative development nationwide, 21M SF, is nearly 3M SF less than overall demand, estimated at 23.8M SF and growing.

Continue reading this story with a free account

Log in or register
Sign up for more articles like this
Subscribe to Bisnow's National Newsletters
Related Stories

Revolution Medicines Nearing Agreement For 700K SF Lease In Redwood City

Trump's New Canadian Tariffs To Spike Additional Materials Costs

Alexandria Sells Cambridge Lab Condo Units For $45M

Wells Fargo Moves To Foreclose On $1.3B Workspace Property Trust Portfolio

Turner Construction Hit With Cyberattack, Hackers Claim Leaks Of Military Info, NDAs

Latest Round Of Fannie Mae Senior Staff Layoffs Has Multifamily Sector Anxious

Why Hines Is Restarting Its Development Engine

How Integrated Infrastructure Can Help AI Data Centers Deploy Faster, Build Smarter

Nvidia Buys Stake In Data Center Power Company

Invesco Cuts Fees, Adds Incentives To Quell Fund Redemption Requests

Investors Anchor Big Capital Into Marinas, Betting On Shallow Supply

Oncology Company Expands Footprint At Hines' Life Sciences Campus